ID:
The panel will discuss the scientific background of the new biomarker, the test performance, initial clinical validation and how it could fit and impact the clinical pathway for Alzheimer’s to try and determine this new and unique tests suitability and potential to improve patients treatment and long term outcomes.
Speakers:
Gerry Móller
Paul Kinnon
Simona Picirrella
Antonio Boniolo
Francesco Granata
Diana Saraceni
Robert Dean
Anne Fagan
Tamas Bartfai
Jeffrey Cummings